Log in

Relevant bibliographies by topics / Mesothelin targeted cancer immunotherapy / Books

Books on the topic 'Mesothelin targeted cancer immunotherapy'

To see the other types of publications on this topic, follow the link: Mesothelin targeted cancer immunotherapy.

Author: Grafiati

Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 30 books for your research on the topic 'Mesothelin targeted cancer immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Yan, Cui, Li Shulin, and SpringerLink (Online service), eds. Targeted Cancer Immune Therapy. New York, NY: Springer-Verlag New York, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

N, Syrigos Konstantinos, and Harrington Kevin J. 1958-, eds. Targeted therapy for cancer. Oxford: Oxford University Press, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Anderson, Kenneth C., Razelle Kurzrock, and Apostolia-Maria Tsimberidou. Targeted therapy in translational cancer research. Hoboken, New Jersey: John Wiley & Sons, Inc., 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Alharbi, Yousef, Manish S. Patankar, and Rebecca J. Whelan. Antibody-Based Therapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0006.

Full text

Abstract:

With their role in connecting disease-associated antigens to the cellular immune response, antibodies hold considerable promise as therapeutic agents. This chapter discusses three classes of therapeutic antibodies that have been developed for use in ovarian cancer therapy. The first includes antibodies selected against tumor-associated antigens such as MUC16/CA125, mesothelin, epithelial cell adhesion molecule, and folate receptor α‎. Antibodies in the second class target proteins such as CTLA-4 and PD1 that act as immune response checkpoint receptors. The third class of antibodies target secreted factors that promote tumor growth: targets in this class include vascular endothelial growth factor, cytokines, and chemokines. The development of each of these is described. The chapter also discusses the complications presented by soluble antigens, which serve to limit the applicability of antigens (such as MUC16/CA125) that are both cell-surface associated and circulating and the prospects for the combination of antibody-based immunotherapy and chemotherapy.

APA, Harvard, Vancouver, ISO, and other styles

5

Williams, William Valentine, Karen Anderson, David B. Weiner, and Cara Haymaker, eds. Targeted Immunotherapy for Cancer. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88976-074-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Li, Shulin, Yan Cui, and Joseph Lustgarten. Targeted Cancer Immune Therapy. Springer New York, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Treating Cancer with Immunotherapy and Targeted Therapy. Mercury Learning & Information, 2019.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Olle, David A. Treating Cancer with Immunotherapy and Targeted Therapy. Mercury Learning & Information, 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Olle, David A. Treating Cancer with Immunotherapy and Targeted Therapy. Mercury Learning & Information, 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Karp, Daniel D., Gerald S. Falchook MD MS, and Joann Lim. Handbook of Targeted Cancer Therapy and Immunotherapy. LWW, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Karp, Daniel D., Joann Lim, and Gerald S. Falchook. Handbook of Targeted Cancer Therapy and Immunotherapy. Lippincott Williams & Wilkins, 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Olle, David A. Treating Cancer with Immunotherapy and Targeted Therapy. Mercury Learning & Information, 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

Handbook of Targeted Cancer Therapy and Immunotherapy: Gastrointestinal Cancer. Lippincott Williams & Wilkins, 2021.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Targeted therapies in oncology. New York: Informa Healthcare, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

Resistance to Immunotherapeutic Antibodies in Cancer Resistance to Targeted AntiCancer Therapeutics. Springer-Verlag New York Inc., 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Markman, Maurie, Kenneth C. Anderson, Razelle Kurzrock, Apostolia-Maria Tsimberidou, and Robert C. Bast. Targeted Therapy in Translational Cancer Research. Wiley & Sons, Incorporated, John, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

Markman, Maurie, Kenneth C. Anderson, Razelle Kurzrock, Bast Robert C. Jr, and Apostolia-Maria Tsimberidou. Targeted Therapy in Translational Cancer Research. Wiley & Sons, Incorporated, John, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

18

Markman, Maurie, Kenneth C. Anderson, Razelle Kurzrock, Bast Robert C. Jr, and Apostolia-Maria Tsimberidou. Targeted Therapy in Translational Cancer Research. Wiley & Sons, Limited, John, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

Targeted Therapies in Oncology. CRC Press, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

20

Giaccone, Giuseppe, and Jean-Charles Soria. Targeted Therapies in Oncology. Taylor & Francis Group, 2019.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

21

Giaccone, Giuseppe, and Jean-Charles Soria. Targeted Therapies in Oncology. Taylor & Francis Group, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

Giaccone, Giuseppe, and Jean-Charles Soria. Targeted Therapies in Oncology. Taylor & Francis Group, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

Giaccone, Giuseppe, and Jean-Charles Soria. Targeted Therapies in Oncology. Taylor & Francis Group, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

(Editor), Giuseppe Giaccone, and Jean-Charles Soria (Editor), eds. Targeted Therapies in Oncology. Informa Healthcare, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

25

Jiang, Tao, Zhu Bo, Shengxiang Ren, and Tetsuya Mitsudomi, eds. Multi-dimensional Biomarkers and Resistance Mechanism of Targeted Therapy and Immunotherapy in Lung Cancer. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-265-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Melanoma Emerging Cancer Therapeutics. Demos Medical Publishing, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

27

Targeted Radionuclide Tumor Therapy Biological Aspects. Springer, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

28

Aljabali, Alaa A., and Kaushik Pal, eds. Bionanotechnology: Next-Generation Therapeutic Tools. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/97898150512781220101.

Full text

Abstract:

Nanoscale technologies are crucial for the characterization and fabrication of biomaterials that are useful in targeted drug delivery systems. New materials enable the delivery of therapeutic agents to specific tissues and cells in order to treat a range of diseases. Bionanotechnology: Next-Generation Therapeutic Tools provides a quick overview of the use of nanomaterials in modern drug delivery and targeted drug therapy systems. The book starts with an overview of nanomaterial toxicity with subsequent chapters detailing their applications in nanomedicine. Concepts such as immunotherapy, cancer theranostics, molecular imaging, aptamers and viral nanoparticles are highlighted in specific chapters. The simplified presentation along with scientific references makes this book ideal for pharmacology and biomedical engineering scholars and life science readers.

APA, Harvard, Vancouver, ISO, and other styles

29

Fancourt, Daisy. Fact file 7: Oncology. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780198792079.003.0020.

Full text

Abstract:

Oncology is a branch of medicine focusing on the prevention, diagnosis, and treatment of cancers; one of the leading causes of death in the world. Early records of cancer have been found in fossils from mummies in ancient Egypt and are discussed in some ancient manuscripts, attesting to the long history of the condition. Oncology teams often encompass medical oncologists (who can specialize in chemotherapy, immunotherapy, hormonal therapy, and targeted therapy), surgical oncologists, radiation oncologists, and doctors with specialities in the organs affected....

APA, Harvard, Vancouver, ISO, and other styles

30

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff, and Madhumita Bhattacharyya. Gynaecological cancers. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0020_update_001.

Full text

Abstract:

Genitourinary cancers examines the malignancies arising in the kidney, ureter, bladder, prostate, testis, and penis. Renal cancer has high propensity for systemic spread, largely mediated by overexpression of vascular endothelial growth factor (VEGF). Treatments include surgery, immunotherapy, and targeted therapy. Wilms tumour, a childhood malignancy of the kidney, warrants specialist paediatric oncology management to provide expertise in its unique pathology, staging, and treatment, often with surgery and chemotherapy. Cancer of the bladder and ureters, another tobacco related cancer, may present as either superficial or invasive disease. The former is managed by transurethral resection and intravesical therapy. The latter may require radical surgery, preoperative chemotherapy, or radiotherapy. Prostate cancer, the commonest male cancer, is an androgen dependent malignancy. It has attracted controversy with regards to PSA screening, and potential over treatment with radical prostatectomy. Division into low, intermediate, and high risk disease according to tumour grade, stage, and PSA helps in deciding best treatment, antiandrogen therapy for metastatic disease, radiotherapy and adjuvant hormone therapy for locally advanced disease, either surgery or radiotherapy for early intermediate risk disease, and active monitoring for low risk cases. Testicular cancer divides according to pathology into seminoma, nonseminomatous germ cell tumours (NSGCT), and mixed tumours, the latter two frequently producing tumour markers, alpha-fetoprotein (AFP) and/or human chorionic gonadotrophin (HCG). Stage I disease is managed by inguinal orchidectomy and surveillance or adjuvant chemotherapy. More advanced disease is managed by chemotherapy, with high probability of cure in the majority. Penile cancer, often HPV related, can be excised when it presents early, but delay in presentation may lead to regional and systemic spread with poor prognosis.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!